Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ROCKET AF: Positive Results For Xarelto, But A Few Chinks In The Armor

This article was originally published in The Pink Sheet Daily

Executive Summary

Rivaroxaban misses two bleeding safety measures, and debate heats up on whether it showed superior efficacy against warfarin.

You may also be interested in...

Results For Bayer's Xarelto In Japanese Phase III Trial In Line With Expectations

TOKYO - Bayer AG's anticoagulant Xarelto (rivaroxaban) met its primary endpoint of clinically relevant bleeding - major and non-major bleeding - in a Japanese Phase III trial, in line with the drug's performance in a 14,000+ global Phase III study, easing the path for approval in Japan

Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products

Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts